Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
May 14 2024 - 10:00AM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with cancer and inflammatory
diseases, today announced an upcoming oral presentation
highlighting new clinical data from Nurix’s orally available,
selective BTK degrader, NX-5948, at the European Hematology
Association Congress which is being held from June 13 - 16, 2024,
in Madrid, Spain, and virtually.
The presentation will summarize updated data from the ongoing
Phase 1a/b study of NX-5948 in heavily pretreated patients with
relapsed/refractory chronic lymphocytic leukemia (CLL) and
non-Hodgkin lymphoma, including patients with BTK inhibitor
resistance mutations and CNS involvement. Among the 10
response-evaluable patients with CLL, the overall response rate at
the January 2024 data cutoff was 70%, demonstrating a deepening of
responses with longer treatment and follow up. Importantly, all
responses remain ongoing as of the January 2024 data cut.
Additional data at higher dose levels and longer treatment
durations will be presented at EHA2024 in June.
Details of the presentation are as follows:
Title: Latest results from an ongoing
first-in-human Phase 1a/b study of NX-5948, a selective Bruton’s
tyrosine kinase (BTK) degrader, in patients with
relapsed/refractory CLL and other B-cell
malignancies.Session: s445 Novel therapies in
relapsed and refractory CLL and hairy cell leukemiaSession
Date and Time: Sunday, June 16, 11:30 a.m. – 12:45 p.m.
CESTLocation: Hall
VelasquezPresenter: Dr. Kim LintonAbstract
#: S155
Abstracts are available on the EHA2024 website and can be
accessed via the Congress website.
About NX-5948
NX-5948 is an investigational, orally bioavailable, small
molecule degrader of Bruton’s tyrosine kinase (BTK). NX-5948 is
currently being evaluated in a Phase 1 clinical trial in patients
with relapsed or refractory B cell malignancies. Nurix has
previously reported that NX-5948 is highly potent against a range
of tumor cell lines that are resistant to current BTK inhibitor
therapies, an important consideration in heavily pretreated CLL/SLL
patient populations. Additional information on the ongoing clinical
trial can be accessed at clinicaltrials.gov (NCT05131022).
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
innovative small molecules and antibody therapies based on the
modulation of cellular protein levels as a novel treatment approach
for cancer, inflammatory conditions, and other challenging
diseases. Leveraging extensive expertise in E3 ligases together
with proprietary DNA-encoded libraries, Nurix has built DELigase,
an integrated discovery platform, to identify and advance novel
drug candidates targeting E3 ligases, a broad class of enzymes that
can modulate proteins within the cell. Nurix’s drug discovery
approach is to either harness or inhibit the natural function of E3
ligases within the ubiquitin-proteasome system to selectively
decrease or increase cellular protein levels. Nurix’s wholly owned,
clinical stage pipeline includes targeted protein degraders of
Bruton’s tyrosine kinase, a B-cell signaling protein, and
inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3
ligase that regulates activation of multiple immune cell types
including T cell and NK cells. Nurix is headquartered in San
Francisco, California. For additional information
visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
Any statements contained herein that do not describe historical
facts, including, but not limited to, statements regarding the
planned timing for the provision of updates and findings from
Nurix’s clinical trials, including Nurix’s intention to present
additional, updated data at the European Hematology Association
Congress in June 2024, are forward-looking statements that involve
risks and uncertainties that could cause actual results to differ
materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, the risks
described under the heading “Risk Factors” in Nurix’s Quarterly
Report on Form 10-Q for the period ended February 29, 2024, and
subsequent filings with the SEC. Any of these risks and
uncertainties could materially and adversely affect Nurix’s
business and results of operations, which could, in turn, have a
significant and adverse impact on Nurix’s stock price. Nurix
cautions you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made. Nurix
undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances
after the date they were made or to reflect the occurrence of
unanticipated events.
Contacts:
InvestorsJason Kantor, Ph.D.Nurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Aug 2023 to Aug 2024